The latest market report published by Credence Research, Inc. “Global Hematopoietic Stem Cells Transplantation Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022,” the hematopoietic stem cells transplantation market was valued at USD 3,741.3 Mn in 2015, and is expected to reach USD 7,796.1 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.
Browse the full report Hematopoietic Stem Cells Transplantation Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/hematopoietic-stem-cells-transplantation-market
Over 50 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.
Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patient’s overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.
Market Competition Assessment:
The hematopoietic stem cells transplantation market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Kite Pharma Inc., Thermo Fisher Scientific, PromoCell, CellGenix Technologie Transfer GmbH, Cesca Therapeutics Inc., R&D Systems, Genlantis, Lonza Group Ltd., TiGenix N.V., and ScienCell Research Laboratories.
Key Market Movements:
- Rising prevalence of leukemia is expected to assist the hematopoietic stem cells transplantation as the survival rates in leukemia patients has been improved after HSCT.
- Future opportunity for HSCT market lies in regenerative Stromal Cell Therapy because it is considered as one of the novel therapies for prevention and treatment of acute graft versus host disease in allogeneic HSCT patients.
- In emerging economies growing government support through providing favorable environments for research laboratories in the field of stem cell research